Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2019-12-11
Target enrollment:
Participant gender:
Summary
This is a multicenter, two part (Part A and Part B) clinical study of CMP-001 administered
intratumorally (IT) and subcutaneously (SC) in combination with atezolizumab with or without
radiation therapy in participants with NSCLC.